Contrafect Corporation (22R)

Overview

ContraFect Corporation, which was founded in 2008 and is based in Yonkers, New York, operated as a clinical-stage biotechnology entity committed to the discovery and development of protein and antibody-based therapies. These therapies were aimed at combating life-threatening and drug-resistant infectious diseases prevalent within the United States. Nevertheless, on December 4, 2023, the company undertook a significant transition by filing for a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. This decision marked a pivotal shift in the company's trajectory, signaling the cessation of its operational endeavors in the biotechnology landscape.

Products and Services

• Exebacase: A forefront product in ContraFect's lineup, Exebacase is a lysin-based therapeutic in Phase III clinical trials targeting staphylococcus aureus infections. This innovative approach addresses a critical need for novel treatments against resistant bacterial strains, potentially revolutionizing the treatment landscape for such infections.
• CF-370: Positioned as an investigational anti-bacterial therapeutic, CF-370 was in Phase 1 clinical trials designed to tackle pseudomonas aeruginosa infections. These infections represent a significant challenge in clinical settings, particularly in conditions like ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and surgical infections, underscoring the critical nature of developing more effective therapeutics.
• CF-296: Identified for its potential against osteomyelitis and prosthetic joint infections (PJI), CF-296 is a preclinical candidate. It showcases the application of engineered lysins in treating joint infections and osteomyelitis, offering hope for patients suffering from these debilitating conditions.
• Exebacase for COVID-19 related infections: Recognizing the unprecedented challenge posed by COVID-19, ContraFect also explored the utility of Exebacase in treating persistent bacteremia caused by methicillin-resistant staphylococcus aureus in affected patients. This extension of Exebacase's application underlines the adaptability of ContraFect's technology in addressing emergent healthcare crises.

In addition to these exciting products, ContraFect had secured a license agreement with The Rockefeller University, focusing on the identification of novel lysin therapeutic candidates targeting gram-negative pathogens. This agreement further amplified the company's commitment to advancing the frontiers of infectious disease treatment through innovative biotechnological tools.